Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1051390

registered interest
date	30/01/2019
answering body	Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Medicine: Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Chancellor of the Exchequer, what fiscal steps he is taking to ensure that the UK has the ability to train sufficient numbers of medical students for the NHS.
tabling member constituency	Preston
tabling member printed	Sir Mark Hendrick
uin	214491
answer	answer is ministerial correction date of answer 06/02/2019 answer text <p>The government is delivering on its commitment to roll out an extra 1,500 medical school places. Around 630 have taken up places on medical courses in September 2018, bringing the total intake for 2018/19 to 6,701 - the highest on record. A further 690 will be available to students in 2019/20 and the remaining 180 places will be available in 2020/21.</p><p> </p><p>The NHS has established a national workforce group, which will look at the future medical workforce as part of delivering on the workforce aims set out in the Long-Term Plan. The NHS will publish a detailed workforce implementation plan in the Spring.</p><p> </p> answering member constituency South West Norfolk answering member printed Elizabeth Truss grouped question UIN 214489 214490 question first answered 06/02/2019 15:57:29 answering member 4097 label Biography information for Elizabeth Truss
tabling member	473 label Biography information for Sir Mark Hendrick

155948

registered interest
date	17/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to encourage flexibility in the licensing process for potential new treatments for rare conditions.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	214491
answer	answer is ministerial correction date of answer 24/11/2014 answer text <p>Most new medicines for rare conditions are licensed by the European Commission.</p><p> </p><p>The European Union offers a range of incentives to encourage the development of these medicines in order to address unmet clinical need. These incentives include a period of 10 years market exclusivity, the provision of Protocol Assistance (scientific advice specifically tailored for orphan medicinal products) and fee reductions and waivers for regulatory procedures.</p><p> </p><p> </p><p> </p><p>Through the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom takes an active role in the decision making process at the European Medicines Agency’s Committee on Orphan Medicinal Products, ensuring applications for Orphan Drug designation of potential drug candidates for rare diseases are appropriately recognised, encouraging companies to develop their products further and recommending use of existing flexibilities such as conditional authorisation, authorisation under exceptional circumstances and accelerated assessment. The UK is actively involved in the European Medicines Agency’s adaptive licensing pilot that is exploring further use of these flexibilities. The MHRA has an Innovation Office that can offer advice and assistance to developers of drugs for rare diseases, including on the use of flexibilities.</p><p> </p><p><strong> </strong></p><p> </p><p>In addition, in the UK, the Early Access to Medicines Scheme aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need.</p><p> </p><p> </p><p> </p><p>We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 24/11/2014 17:23:13 answering member 4020 label Biography information for George Freeman
tabling member	3960 label Biography information for Henry Smith